神经母细胞瘤CCCG-NB-2015共识多中心应用总结

靳燕,  袁晓军,  赵强,  李府,  李建新,  江莲,  卢俊,  戴云鹏,  赵平,  詹江华,  李杰,  曹嫣娜,  李璋琳,  杨嘉兴,  李忠元,  王道威,  龚宝成,  闫杰

downloadPDF
文章导航 > 中国肿瘤临床  > 2023 >  50(9): 433-442
靳燕, 袁晓军, 赵强, 李府, 李建新, 江莲, 卢俊, 戴云鹏, 赵平, 詹江华, 李杰, 曹嫣娜, 李璋琳, 杨嘉兴, 李忠元, 王道威, 龚宝成, 闫杰. 神经母细胞瘤CCCG-NB-2015共识多中心应用总结[J]. 中国肿瘤临床, 2023, 50(9): 433-442. doi: 10.12354/j.issn.1000-8179.2023.20221693
引用本文: 靳燕, 袁晓军, 赵强, 李府, 李建新, 江莲, 卢俊, 戴云鹏, 赵平, 詹江华, 李杰, 曹嫣娜, 李璋琳, 杨嘉兴, 李忠元, 王道威, 龚宝成, 闫杰. 神经母细胞瘤CCCG-NB-2015共识多中心应用总结[J]. 中国肿瘤临床, 2023, 50(9): 433-442. doi: 10.12354/j.issn.1000-8179.2023.20221693
shu
Yan Jin, Xiaojun Yuan, Qiang Zhao, Fu Li, Jianxin Li, Lian Jiang, Jun Lu, Yunpeng Dai, Ping Zhao, Jianghua Zhan, Jie Li, Yanna Cao, Zhanglin Li, Jiaxing Yang, Zhongyuan Li, Daowei Wang, Baocheng Gong, Jie Yan. Summary of the multicenter application of the CCCG-NB-2015 consensus in neuroblastoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(9): 433-442. doi: 10.12354/j.issn.1000-8179.2023.20221693
Citation: Yan Jin, Xiaojun Yuan, Qiang Zhao, Fu Li, Jianxin Li, Lian Jiang, Jun Lu, Yunpeng Dai, Ping Zhao, Jianghua Zhan, Jie Li, Yanna Cao, Zhanglin Li, Jiaxing Yang, Zhongyuan Li, Daowei Wang, Baocheng Gong, Jie Yan. Summary of the multicenter application of the CCCG-NB-2015 consensus in neuroblastoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(9): 433-442. doi: 10.12354/j.issn.1000-8179.2023.20221693
shu

神经母细胞瘤CCCG-NB-2015共识多中心应用总结

doi: 10.12354/j.issn.1000-8179.2023.20221693
  • 1.

    天津医科大学肿瘤医院儿童肿瘤科，国家恶性肿瘤临床医学研究中心，天津市"肿瘤防治"重点实验室，天津市恶性肿瘤临床医学研究中心（天津市300060）

  • 2.

    上海交通大学医学院附属新华医院血液肿瘤科

  • 3.

    山东大学附属儿童医院（济南市儿童医院）血液肿瘤科

  • 4.

    武汉市儿童医院血液科

  • 5.

    河北医科大学第四医院儿科

  • 6.

    苏州大学附属儿童医院血液科

  • 7.

    山东省立医院儿科

  • 8.

    天津市儿童医院普外科

基金项目: 本文课题受国家重点研发计划项目（编号：2018YFC1313000）和天津市医学重点学科（专科）建设项目（编号：TJYXZDXK-009A）资助
详细信息
    作者简介:

    靳燕：专业方向为儿童恶性肿瘤临床及基础研究

    通讯作者:

    闫杰　yanjie631016@126.com

Summary of the multicenter application of the CCCG-NB-2015 consensus in neuroblastoma

  • 1.

    Department of Pediatric Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention & Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

  • 2.

    Department of Hematology and Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

  • 3.

    Department of Hematology and Oncology, Children's Hospital Affiliated to Shandong University, Jinan 250022, China

  • 4.

    Department of Hematology, Wuhan Children's Hospital,Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430015, China

  • 5.

    Department of Pediatrics，The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

  • 6.

    Department of Hematology，Children's Hospital of Soochow University, Suzhou 215002, China

  • 7.

    Department of Pediatrics，Shandong First Medical University Affiliated Provincial Hospital, Jinan 250021, China

  • 8.

    Department of Surgery, Tianjin Children's Hospital, Tianjin 300134, China

Funds: This work was supported by National Key R&D Program of China (No. 2018YFC1313000）and Tianjin Key Medical Discipline (Specialty) Construction Project（No. TJYXZDXK-009A）
More Information

    摘要
  • 摘要:   目的  对中国多中心应用CCCG-NB-2015共识方案诊治的儿童神经母细胞瘤（neuroblastoma，NB）病例进行回顾性分析总结，以期为改进NB诊疗工作提供有力依据。  方法  回顾性分析2013年3月至2020年7月经统一规范的CCCG-NB-2015共识方案诊治的全国多中心500例NB患儿的临床和预后资料，通过Cox单因素和多因素回归分析明确影响NB预后的关键因素；分别绘制神经元特异性烯醇化酶（neuron-specific enolase，NSE）和乳酸脱氢酶（lactate dehydrogenase，LDH）在预测骨髓转移和复发的ROC曲线，明确NSE和LDH的临床价值；比对分析NB两种不同分期系统和危险度分组系统下患儿的预后差异，着重分析中危组人群的队列特征和预后结局。  结果  通过单因素分析共确定10个潜在的预后因子，分别为年龄、肿瘤原发部位、INPC分类、骨髓转移、MYCN状态、INSS分期、INRGSS分期、诊断时NSE、LDH水平和影像学定义的危险因素（image-defined risk factors，IDRFs），均P<0.05。Cox多因素分析结果显示与无事件生存率（event-free survival，EFS）密切相关的独立预后因子为INPC分类、骨髓转移、诊断时NSE、LDH水平，与OS密切相关的独立预后因子为NSE、LDH水平及INRGSS分期（均P<0.05）；NSE和LDH可以较好地预测NB骨髓转移、复发等事件发生（均P<0.05)；INSS分期中非4期和4期的3年EFS分别为93.8%和52.6%；转换为INRGSS分期后，L1、L2、MS和M期的3年EFS分别为94.4%、87.2%、87.5%和53.6%。低危组、中危组和高危组3年和5年的EFS分别为97.1%和97.1%、90.0%和87.3%、53.9%和47.3%；其中INSS分期中3期且伴有INPC为UH型的患儿在CCCG-NB-2015共识方案中被归入高危组，其预后差，5年EFS为65.7%（P<0.05），但却在INRG危险度分组中被列入中危组。  结论  NSE和LDH水平在预测NB患儿骨髓是否转移以及预后评价方面具有重要价值。INRGSS分期为预后的独立影响因子，其较INSS分期在对患儿预后评估方面更具有临床意义，推荐使用INRGSS分期系统；CCCG-NB-2015共识方案各危险度分组治疗下低中危组预后较好，高危组预后较差，建议将来可降低低危组的治疗强度，而对于基于INRG危险度分组治疗的前提下，中危组的治疗建议继续延用CCCG-NB-2015共识中危组方案。

     

    Abstract:   Objective  : To analyze and summarize the cases of neuroblastoma (NB) in children diagnosed and treated by the multi-center application of CCCG-NB-2015 consensus scheme in China, in order to provide a strong basis for improving the diagnosis and treatment of NB.   Methods  The clinical and prognostic data of 500 patients with NB from multiple centers nationwide diagnosed and treated by the unified and standardized CCCG-NB-2015 program were retrospectively analyzed from March 2013 to July 2020, and the key factors affecting the prognosis of NB were identified through Cox univariate and multivariate regression analysis. The ROC curves of NSE and LDH in predicting bone marrow metastasis and recurrence were plotted, and the clinical value of neuron-specific enolase (NSE) and lactate dehydrogenase (LDH) was clarified. The prognostic differences of patients under the two different stages of NB and the risk group system were compared, and the cohort characteristics and prognostic outcomes of the cohort population in the intermediate-risk group were analyzed.   Results  A total of 10 potential prognostic factors were identified by univariate analysis, namely age, tumor primary site, INPC classification, bone marrow infiltration, MYCN gene amplification status, INSS stage, INRGSS stage, NSE and LDH levels at diagnosis, and IDRFs (P<0.05). The results of Cox multivariate analysis showed that the independent prognostic factors closely related to event-free survival (EFS) were INPC classification, bone marrow infiltration, NSE and LDH levels at diagnosis, and the independent prognostic factors closely related to OS were NSE, LDH level and INRGSS stage (P<0.05). NSE and LDH can well predict events such as NB bone marrow metastasis and recurrence (P<0.05). The 3-year EFS of INSS 4 and non-INSS 4 was 93.8% and 52.6% respectively. After conversion to INRGSS staging, the 3-year EFS for L1, L2, MS and M were 94.4%, 87.2%, 87.5% and 53.6%, respectively. The EFS at 3 and 5 years in the low-risk, intermediate-risk and high-risk groups were 97.1% and 97.1%, 90.0% and 87.3%, 53.9% and 47.3%, respectively. Among them, patients with stage INSS 3 with UH of INPC were classified as high-risk group in the CCCG-NB-2015 protocol, and their prognosis was poor, with a 5-year EFS of 65.7% (P<0.05), but mostly classified as intermediate-risk in the INRG risk group.   Conclusions  NSE and LDH levels are of great value in predicting whether bone marrow metastasis and prognosis evaluation in NB patients. INRGSS staging is an independent prognostic factor and has more clinical significance in assessing prognosis than INSS staging, and the INRGSS staging system is recommended. The prognosis of the low- and medium-risk group was better under the treatment of each risk group of the CCCG-NB-2015 regimen, and the prognosis of the high-risk group was poor. It is suggested that the treatment intensity of low-risk group can be reduced in the future. Under the premise of INRG risk group therapy, the regimen of the intermediate-risk group continued to be CCCG-NB-2015 for the intermediate-risk group.

     

    • HTML全文

  • 图  1  NSE和LDH对NB患儿骨髓转移、复发的ROC曲线

    A：骨髓转移；B：复发

    下载: 全尺寸图片 幻灯片

    图  3  不同危险度分组及INSS 3期中FH和UH型患儿的EFS和OS分析

    A：不同危险度分组的EFS和OS生存曲线；B：INSS 3期中高危人群占比及FH和UH型患儿的EFS生存曲线

    下载: 全尺寸图片 幻灯片

    图  2  不同分期占比及EFS生存曲线

    A：INRGSS中L1和L2占比及EFS生存曲线；B：各INSS分期占比及EFS生存曲线；C：各INRGSS分期占比及EFS生存曲线

    下载: 全尺寸图片 幻灯片

    表  1  CCCG-NB-2015共识具体化疗方案与COG同时期化疗方案对比

    危险度分组CCCG-NB-2015COG参考方案
    疗程（个）　　　　方案疗程（个）　　　　　方案
    低危组1　CBP+VP-161　　CBP+VP-16COG P9641[12]
    2　CBP+CTX+ADR2　　CBP+CTX+ADR
    3　CTX+VP-163　　VP-16+CTX
    4　CBP+CTX+ADR4　　CBP+VP-16+ADR
    5　CTX+VP-16—　　　　　　—
    6　CBP+CTX+ADR—　　　　　　—
    7　CBP+VP-16—　　　　　　—
    8　CTX+ADR—　　　　　　—
    中危组1　VCR+CDDP+ADR+CTX1　　CBP+VP-16COG ANBL0531[13]
    2　VCR+CDDP+VP-16+CTX2　　CBP+CTX+ADR
    3　VCR+CDDP+ADR+CTX3　　CTX+VP-16
    4　VCR+CDDP+VP-16+CTX4　　CBP+CTX+ADR
    5　VCR+CDDP+ADR+CTX5　　CTX+VP-16
    6　VCR+CDDP+VP-16+CTX6　　CBP+CTX+ADR
    7　VCR+CDDP+ADR+CTX7　　CBP+VP-16
    8　VCR+CDDP+VP-16+CTX8　　CTX+ADR
    高危组1　CTX+TOPO1　　CTX+TOPOCOG ANBL0532[14]
    2　CTX+TOPO2　　CTX+TOPO
    3　CDDP+VP-163　　CDDP+VP-16
    4　CTX+DOXO+VCR+MESNA4　　CTX+DOXO+VCR+MESNA
    5　CDDP+VP-165　　CDDP+VP-16
    6　CTX+DOXO+VCR+MESNA6　　CTX+DOXO+VCR+MESNA
    7　CTX+TOPO—　　　　　　—
    8　CDDP+VP-16—　　　　　　—
    CBP：卡铂；VP-16：依托泊苷；CTX：环磷酰胺；ADR：阿霉素；VCR：长春新碱；CDDP：顺铂；MESNA：美司钠；TOPO：拓扑替康；DOXO：阿霉素
    下载: 导出CSV

    表  2  500例NB患儿临床特征及单因素和多因素的预后分析

    临床特征例数（%）EFS单因素分析EFS多因素分析OS单因素分析OS多因素分析
    HR（95%CI）PHR（95%CI）PHR（95%CI）PHR（95%CI）P
    性别0.982—0.244—
    　男280（56.0）0.996（0.709～1.400）—1.285（0.842～1.961）—
    　女220（44.0）1.000—1.000—
    诊断时年龄（月）<0.001—<0.001—
    　<18147（29.4）1.000—1.000—
    　≥18353（70.6）2.962（1.802～4.868）—2.951（1.607～5.418）—
    原发部位<0.001—<0.001—-
    　腹膜后339（67.8）1.000—1.000—
    　纵隔128（25.6）0.248（0.140～0.442）—0.250（0.125～0.498）—
    　其他33（6.6）0.809（0.424～1.546）—0.454（0.166～1.239）—
    INPC分类<0.0010.0040.001—
    　FH230（46.0）1.0001.0001.000—
    　UH196（39.2）3.279（2.181～4.930）1.924（1.267～2.920）2.483（1.556～3.963）—
    　不详74（14.8）2.980（1.747～5.083）3.110（1.267～5.317）2.128（1.094～4.137）—
    骨髓转移<0.0010.001<0.001—
    　是201（40.2）4.421（3.042～6.427）1.0005.459（3.373～8.834）—
    　否299（59.8）1.0000.505（0.334～0.765）1.000—
    MYCN状态<0.001—<0.001—
    　未扩增78（15.6）1.000—1.000—
    　扩增365（73.0）2.762（1.841～4.146）—2.801（1.736～4.520）—
    　不详57（11.4）2.263（1.430～3.583）—1.671（0.911～3.067）—
    INSS分期（期）<0.001—<0.001 —
    　1～3，4S246（49.2）1.000—1.000—
    　4254（50.8）6.135（3.879～9.704）—8.548（4.542～16.087）—
    INRGSS分期（期）<0.001——<0.0010.001
    　L1157（31.4）1.000—1.0001.000
    　L281（16.2）3.346（1.387～8.072）—8.135（1.727～38.315）3.946（0.814～19.13）
    　M/MS262（52.4）10.776（5.255～22.097）—30.259（7.431～123.22）9.849（2.261～42.912）
    NSE（ng/mL）<0.0010.006<0.0010.175
    　<200285（57.0）1.0001.0001.0001.000
    　≥200184（36.8）6.0842.302（1.384～3.828）7.140（4.299～11.856）1.821（0.971～3.414）
    　不详31（6.2）00（0～4.834E+132）0（0～1.835E+181）0（0～1.353E+165）
    LDH（U/L）<0.0010.002<0.0010.002
    　<500227（55.4）1.0001.0001.0001.000
    　≥500181（36.2）5.558（3.762～8.213）2.397（1.484～3.871）7.574（4.507～12.73）2.912（1.563～5.423）
    　不详42（8.4）1.023（0.430～2.435）1.414（0.589～3.397）0.933（0.274～3.176）1.117（0.326～3.823）
    IDRFs<0.001—<0.001—
    　有259（51.8）2.547（1.754～3.700）—2.546（1.614～4.017）—
    　无241（48.2）1.000　—　1.000　—　
    下载: 导出CSV

    表  3  INSS分期和INRGSS的转化及占比 例（%）

    INRGSSINSS分期（期）合计（%）
    123
    L173（46.5）36（22.9）48（30.6）157（66.0）
    L24（4.9）7（8.6）70（86.4）81（34.0）
    合计77（32.4）43（18.1）118（49.6）238（100.0）
    下载: 导出CSV

    表  4  CCCG-NB-2015共识方案和COG方案5年EFS与OS对比 %

    危险度分组CCCG-NB-2015COG[5]
    5年EFS5年OS5年EFS5年OS
    低危组97.197.889.497.9
    中危组87.392.986.194.9
    高危组47.357.350.861.9
    下载: 导出CSV
    • 参考文献(17)
  • [1] Qiu B, Matthay KK. Advancing therapy for neuroblastoma[J]. Nat Rev Clin Oncol, 2022, 19(8):515-533. doi: 10.1038/s41571-022-00643-z
    [2] Cohn SL, Pearson AD, London WB, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report[J]. J Clin Oncol, 2009, 27(2):289-297. doi: 10.1200/JCO.2008.16.6785
    [3] 中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科学分会肿瘤外科学组.儿童神经母细胞瘤诊疗专家共识[J].中华小儿外科杂志,2015,36(1):3-7.
    [4] 中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科学分会肿瘤学组.儿童神经母细胞瘤诊疗专家共识CCCG-NB-2021方案[J].中华小儿外科杂志,2022,43(7):588-598.
    [5] Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the children’s oncology group[J]. J Clin Oncol, 2021, 39(29):3229-3241. doi: 10.1200/JCO.21.00278
    [6] Liang WH, Federico SM, London WB, et al. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future[J]. JCO Clin Cancer Inform, 2020, 4:895-905.
    [7] Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oncol, 1993, 11(8):1466-1477. doi: 10.1200/JCO.1993.11.8.1466
    [8] Burchill SA, Beiske K, Shimada H, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group[J]. Cancer, 2017, 123(7):1095-1105. doi: 10.1002/cncr.30380
    [9] Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the international neuroblastoma risk group project[J]. Radiology, 2011, 261(1):243-257. doi: 10.1148/radiol.11101352
    [10] Georgantzi K, Sköldenberg EG, Stridsberg M, et al. Chromogranin A and neuron-specific enolase in neuroblastoma: correlation to stage and prognostic factors[J]. Pediatr Hematol Oncol, 2018, 35(2):156-165. doi: 10.1080/08880018.2018.1464087
    [11] Moreno L, Guo DJ, Irwin MS, et al. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: an international neuroblastoma risk group poject[J]. Pediatr Blood Cancer, 2021, 68(3):e28794.
    [12] Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of children’s oncology group study P9641[J]. J Clin Oncol, 2012, 30(15):1842-1848. doi: 10.1200/JCO.2011.37.9990
    [13] Twist CJ, Schmidt ML, Naranjo A, et al. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the children’s oncology group study ANBL0531[J]. J Clin Oncol, 2019, 37(34):3243-3255. doi: 10.1200/JCO.19.00919
    [14] Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial[J]. JAMA, 2019, 322(8):746-755. doi: 10.1001/jama.2019.11642
    [15] 朱富艺,闫杰,曹嫣娜,等.血清神经元特异性烯醇化酶和尿香草扁桃酸与神经母细胞瘤临床病理特征的相关性[J].中国肿瘤临床,2019,46(22):1160-1166.
    [16] Moroz V, Machin D, Hero B, et al. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the international neuroblastoma risk group (INRG) project[J]. Pediatr Blood Cancer, 2020, 67(8):e28359.
    [17] Joshi VV, Cantor AB, Brodeur GM, et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group[J]. Cancer, 1993, 71(10):3173-3181. doi: 10.1002/1097-0142(19930515)71:10<3173::AID-CNCR2820711045>3.0.CO;2-P
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
图(3) / 表(4)
计量
  • 文章访问数:  66
  • HTML全文浏览量:  9
  • PDF下载量:  17
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-12-02
  • 录用日期:  2023-04-17
  • 修回日期:  2023-04-17

目录

    /

    返回文章
    返回

    版权所有 © 2013《中国肿瘤临床》编辑部津ICP备09011441号-3

    地址：天津市河西区体院北环湖西路肿瘤医院内 300060电话/传真：(022)23527053Email：cjco@cjco.cn

    本系统由北京仁和汇智信息技术有限公司开发    百度统计